Search Results - Baumert, Thomas

Thomas Baumert

Thomas Baumert (born May 20, 1965) is a German-French physician-scientist and entrepreneur. He is a Professor of Medicine at the University of Strasbourg and the Chief of the Gastroenterology-Hepatology Service at the . He is the founder of Alentis Therapeutics, a clinical-stage biotech company in Basel. He works on the basic, translational, and clinical investigation of liver disease and cancer.

Baumert and his teams have discovered and developed novel strategies to treat fibrosis and cancer. He has published more than 400 scientific articles including in ''The New England Journal of Medicine'', ''Cell'', ''Nature'', and ''Science Translational Medicine''. His work has been recognized by several awards and honors, including the Galien Prize and the Inserm Research Award. Provided by Wikipedia
  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy

    Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy by Khera, Tanvi, Todt, Daniel, Vercauteren, Koen, McClure, C. Patrick, Verhoye, Lieven, Farhoudi, Ali, Bhuju, Sabin, Geffers, Robert, Baumert, Thomas, Steinmann, Eike, Meuleman, Philip, Pietschmann, Thomas, Brown, Richard J.P.

    Published 2017
    Get full text
  2. 2
    Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin

    Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin by Tawar, Rajiv G., Heydmann, Laura, Bach, Charlotte, Schüttrumpf, Jörg, Chavan, Shailesh, King, Barnabas J., McClure, C. Patrick, Ball, Jonathan K., Pessaux, Patrick, Habersetzer, François, Bartenschlager, Ralf, Zeisel, Mirjam B., Baumert, Thomas

    Published 2016
    Get full text
  3. 3
    A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo

    A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo by Desombere, Isabelle, Mesalam, Ahmed Atef, Urbanowicz, Richard A., Van Houtte, Freya, Verhoye, Lieven, Keck, Zhen-Yong, Farhoudi, Ali, Vercauteren, Koen, Weening, Karin E., Baumert, Thomas F., Patel, Arvind H., Foung, Steven K.H., Ball, Jonathan, Leroux-Roels, Geert, Meuleman, Philip

    Published 2017
    Get full text
  4. 4
    Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice

    Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice by Vercauteren, Koen, Brown, Richard J.P., Mesalam, Ahmed Atef, Doerrbecker, Juliane, Bhuju, Sabin, Geffers, Robert, Van Den Eede, Naomi, McClure, C. Patrick, Troise, Fulvia, Verhoye, Lieven, Baumert, Thomas, Farhoudi, Ali, Cortese, Riccardo, Ball, Jonathan K., Leroux-Roels, Geert, Pietschmann, Thomas, Nicosia, Alfredo, Meuleman, Philip

    Published 2016
    Get full text

Search Tools: